Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: 2013 International Congress on Vascular Dementia
Guest editors: Amos D. Korczyn
Article type: Review Article
Authors: Giannopoulos, Sotiriosa; 1; * | Katsanos, Aristeidis H.a; 1 | Kosmidou, Mariab | Tsivgoulis, Georgiosc; d
Affiliations: [a] Department of Neurology, School of Medicine, University of Ioannina, Ioannina, Greece | [b] 1st Division of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece | [c] Second Department of Neurology, Medical School, University of Athens, Athens, Greece | [d] International Clinical Research Center, Department of Neurology, St. Anne's University Hospital in Brno, Brno, Czech Republic
Correspondence: [*] Correspondence to: Sotirios Giannopoulos, MD, PhD, Department of Neurology, School of Medicine, University of Ioannina, University Campus, 45110, Ioannina, Greece. Tel.: +30 26510 07514; Fax: +30 26510 07011; E-mail: sgiannop@uoi.gr.
Note: [1] These authors contributed equally to this work.
Abstract: The impact of statin therapy on dementia has been a hot topic of debate over the last decade and still remains highly controversial. Among all causes of dementia, vascular dementia (VaD) is the one type that is more likely to benefit from statins. To date no randomized clinical trials have been published and no systematic review has investigated a possible preventive effect of statins on the VaD subtype. In the present literature review, we tried to identify all available data on the effect of statins specifically in patients with VaD, and to further discuss this possible association. Our literature search highlighted two cross-sectional studies, two prospective cohort studies, and one retrospective cohort study. Two of the studies found a significant positive effect of statin treatment on VaD, depicted by the lower incidence of VaD in statin users, while the others reported non-significant associations. The relatively small numbers of VaD patients and statin users, as well as the presence of confounders and biases, make the interpretation of results extremely difficult. Statins may exert a benefit in the prevention of all-type dementia and VaD, through several mechanisms except for hyperlipidemia reduction. A well-designed randomized clinical trial is the ideal study design to address the effect of statin therapy in VaD and to draw final conclusions.
Keywords: Cholesterol, HMG-CoA inhibitors, lipid lowering agents, statins, vascular dementia
DOI: 10.3233/JAD-132366
Journal: Journal of Alzheimer's Disease, vol. 42, no. s3, pp. S315-S320, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl